News
Tralokinumab use in patients with head and neck atopic dermatitis was associated with sustained improvements with up to 4 years of treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback